Navigation Links
Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines
Date:9/19/2012

PHILADELPHIA, Sept. 19, 2012 /PRNewswire/ -- Ten leading biopharmaceutical companies announced today that they have formed a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi launched TransCelerate BioPharma Inc. ("TransCelerate"), the largest ever initiative of its kind, to identify and solve common drug development challenges with the end goals of improving the quality of clinical studies and bringing new medicines to patients faster.

Through participation in TransCelerate, each of the ten founding companies will combine financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment. Together, member companies have agreed to specific outcome-oriented objectives and established guidelines for sharing meaningful information and expertise to advance collaboration.   

"There is widespread alignment among the heads of R&D at major pharmaceutical companies that there is a critical need to substantially increase the number of innovative new medicines, while eliminating inefficiencies that drive up R&D costs," said newly appointed acting CEO of TransCelerate BioPharma, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate Vice President, Science & Technology, Johnson & Johnson.  "Our mission at TransCelerate BioPharma is to work together across the global research and development community and share research and solutions that will simplify and accelerate the delivery of exciting new medicines for patients."

Members of TransCelerate have identified clinical study execution as the initiative's initial area of focus. Five projects have been selected by the group for funding and development, incl
'/>"/>

SOURCE TransCelerate BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced that it ... call and webcast on Thursday, August 13, 2015 at ... webcast will follow the release of fiscal 2016 first ... be available approximately two hours after the call at ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... BC , Aug. 3, 2015 /PRNewswire/ - RepliCel Life ... medicine company focused on the development of autologous cell therapies, ... be presenting at the InvestMNT conference held in ... 8:15 AM local time. Hall,s presentation will highlight RepliCel,s 18-month ... sale in Europe , clinical data from ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Feb. 24, 2011 ViroPharma Incorporated (Nasdaq: VPHM ... and year ended December 31, 2010. In 2010, ... net product sales, including $177 million in net sales of ... income of $157 million, representing 88 percent growth over the ...
... DIEGO, Feb. 23, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of its previously announced public offering of common stock ... additional 412,500 shares of common stock to cover overallotments. ... shares offered at a price to the public of $26.00 per ...
... 2011 Quanterix Corporation, a single molecule diagnostics company ... and in vitro diagnostics markets, today announced the online ... Si ngle Mo lecule A rray ... one straightforward measurement.  The article appears in the journal ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 11Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering 2Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering 3Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability 2
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 2010 Country roadways can be hazardous for moose and ... elk and caribou in North America and Europe each year. ... pools that collect following pavement deicing. Because moose ... weighing up to 720 kilograms, their salt cravings can pose ...
... the Free State in South Africa (Ren Fourie and Charles ... (Rudy Jocqu) discovered very poorly known purse-web spiders of the ... new to science. The study was published in the open ... unique about purse-web spiders is that, in contrast to trapdoor ...
... have shown that a new experimental vaccine helps to ... from CSIRO,s Australian Animal Health Laboratory (AAHL) will announce ... Australian Veterinary Association conference in Adelaide today. "Our ... the infection of horses with Hendra virus," Dr Middleton ...
Cached Biology News:Of moose and men 2Vaccine protects from deadly Hendra virus 2
... The ApopTag Fluorescein Direct ... detects apoptotic cells in situ ... The DNA fragments are tagged ... nucleotide. The kit provides fluorescence ...
... CHEMICON APO-BRDU Kit is a ... breaks and total cellular DNA to detect ... kit contains the instructions and reagents required ... and negative control cells for assessing reagent ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... The Biomek FXP is the latest entry in ... greater positional accuracy and increased robustness, it can ... It can be configured with either one or ... the Biomek FXP sets the standard for flexible ...
Biology Products: